Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor physical status / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 317-319, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-348103
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of a weekly schedule of low dose-intensity docetaxel monochemotherapy for patients with anthracycline-resistant metastatic breast cancer (MBC) in poor physical status.</p><p><b>METHODS</b>Thirty MBC patients who were previously exposed to anthracycline treatment received docetaxel alone at a dose of 30 mg/m2 on D1, D8 and D15, repeated every 4 weeks for a maximum of 6 cycles.</p><p><b>RESULTS</b>Of the 30 evaluable patients, 2 (6.7%) achieved a complete response, and 9 (30.0%) a partial response, with an overall objective response rate of 36.7% (95% CI 20.5%-53.9%). The most common adverse event was hematologic toxicity. After an average follow-up of 15.0 months, the median time to progression (TTP) was 8. 5 months and the median overall survival (OS) had not reached yet at the end of follow-up.</p><p><b>CONCLUSION</b>The weekly low dose-intensity docetaxel monochemotherapy is effective and well-tolerated in patients with anthracycline-resistant metastatic breast cancer in poor physical status.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Remission Induction
/
Breast Neoplasms
/
Survival Rate
/
Follow-Up Studies
/
Carcinoma, Lobular
/
Carcinoma, Ductal, Breast
/
Drug Resistance, Neoplasm
/
Anthracyclines
/
Taxoids
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS